FDA awards C-Path major grant for cardiovascular disease research

The U.S. Food and Drug Administration granted Tucson-based Critical Path Institute (C-Path) $675,000 to fund the initial year of what is expected to be a multiyear, multiphase research program to develop "personalized" therapies for patients with cardiovascular disease.

C-Path, which aims to implement the FDA's Critical Path Initiative by developing faster, safer, and smarter pathways to new medical products, will collaborate with University of Utah and nonprofit health system Intermountain Health Care, both based in Salt Lake City.

"This is exactly the kind of project that we envisioned when we established our collaborative relationship with C-Path," said Dr. Janet Woodcock, deputy commissioner of the FDA.

"The external peer review group gave this project high marks because it brings together scientists from the FDA, C-Path, industry and academia to advance personalized medicine."

If the program is successful in its first year, it could generate up to $2 million in additional funding over the next three years.

---

For more information:

"Industry news and notes," Arizona Daily Star, 09/14/2006

"C-Path receives $675,000 award for FDA collaboration," C-Path press release, 09/13/2006